Receptor News and Research

RSS

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Perimenopausal lifestyle modifications could reduce risk of breast cancer in obese woman

Obese women might be able to eliminate their increased risk for postmenopausal breast cancer by taking measures during perimenopause to prevent weight gain and to therapeutically control the metabolic effects of their obesity, according to the results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

10 Dec 2012

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

10 Dec 2012

C5aRA treatment could be effective against periodontitis

Periodontitis, a form of chronic gum disease that affects nearly half of the U.S. adult population, results when the bacterial community in the mouth becomes unbalanced, leading to inflammation and eventually bone loss. In its most severe form, which affects 8.5 percent of U.S. adults, periodontitis can impact systemic health.

9 Dec 2012

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

7 Dec 2012

Novel antidepressant targets brain receptors responsible for learning and memory

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

7 Dec 2012

Drug offers alternative treatment strategy for insomnia

Orexin receptor antagonism may offer a novel treatment approach to insomnia, clinical findings suggest.

7 Dec 2012

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.

7 Dec 2012

Positive results from NanoString's second clinical study of PAM50-based breast cancer assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced positive results from the second clinical validation study of its in vitro diagnostic breast cancer assay based on the PAM50 gene expression signature.

From NanoString Technologies 7 Dec 2012

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Whole genome sequencing has revealed previously unreported mutations in metastatic triple-negative breast cancer (TNBC), according to a study published by the journal Molecular Cancer Therapeutics.

6 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Researchers unlock mechanisms of how the body converts dietary carbohydrates into fat

A gene that helps the body convert that big plate of holiday cookies you just polished off into fat could provide a new target for potential treatments for fatty liver disease, diabetes and obesity.

6 Dec 2012

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

6 Dec 2012

Western University research could lead to better treatments for PTSD and drug addiction

New research from Western University could lead to better treatments for Post-Traumatic Stress Disorder (PTSD) and drug addiction by effectively blocking memories. The research performed by Nicole Lauzon, a PhD candidate in the laboratory of Steven Laviolette at Western's Schulich School of Medicine & Dentistry has revealed a common mechanism in a region of the brain called the pre-limbic cortex, can control the recall of memories linked to both aversive, traumatic experiences associated with PTSD and rewarding memories linked to drug addiction.

6 Dec 2012

‘Pain as reward’ raises tolerance threshold

An individual’s ability to tolerate pain is influenced by their preconceptions and beliefs about the meaning of the pain, Italian researchers have shown.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Researchers investigate GPER receptor as possible new drug target for breast cancer

Five-year breast cancer survival rates have improved dramatically over the past 50 years, but tumors can recur up to ten or more years after they are detected. When tumors recur, they are even more difficult to treat.

5 Dec 2012

Rethinking therapy decisions in autoimmune encephalopathy

Researchers say that diagnosis and management of encephalopathies may need to be rethought, as many patients who test negative for the relevant antibody still benefit from immunotherapy.

4 Dec 2012

Receptor News and Research

New study could help develop anti-inflammatory drugs with fewer side effects

New hope for leukemia patients

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Perimenopausal lifestyle modifications could reduce risk of breast cancer in obese woman

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

C5aRA treatment could be effective against periodontitis

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Novel antidepressant targets brain receptors responsible for learning and memory

Drug offers alternative treatment strategy for insomnia

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Positive results from NanoString's second clinical study of PAM50-based breast cancer assay

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Researchers unlock mechanisms of how the body converts dietary carbohydrates into fat

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Western University research could lead to better treatments for PTSD and drug addiction

‘Pain as reward’ raises tolerance threshold

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Researchers investigate GPER receptor as possible new drug target for breast cancer

Rethinking therapy decisions in autoimmune encephalopathy

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News